Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2017 Corporate Update and Results
27 févr. 2018 16h01 HE
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Feb. 27, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Tuesday,...
Editas Medicine to Participate in Upcoming Investor Conferences
08 févr. 2018 16h01 HE
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will participate in two upcoming investor...
Editas Medicine to Present at the 36th Annual J.P. Morgan Healthcare Conference
03 janv. 2018 08h57 HE
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will present a company overview followed by a...
Editas Medicine Announces Third Quarter 2017 Results and Update
07 nov. 2017 16h03 HE
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today reported financial results for the third quarter ended September 30,...
Editas Medicine to Host Conference Call Discussing Third Quarter 2017 Corporate Update and Results
03 nov. 2017 08h00 HE
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Nov. 03, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Tuesday,...
Editas Medicine to Participate in Investor Conferences in October
03 oct. 2017 08h00 HE
|
Editas Medicine
CAMBRIDGE, Mass., Oct. 03, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that management will participate in two upcoming investor...
Editas Medicine to Participate in Morgan Stanley 15th Annual Global Healthcare Conference
05 sept. 2017 08h00 HE
|
Editas Medicine
CAMBRIDGE, Mass., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that management will participate in a fireside chat at the...
Editas Medicine Announces Second Quarter 2017 Results and Update
09 août 2017 16h03 HE
|
Editas Medicine
Leber Congenital Amaurosis type 10 (LCA10) product candidate EDIT-101 made significant progress toward clinical trials Achieved research milestone in Juno Therapeutics, Inc., collaboration ...
Editas Medicine to Host Conference Call Discussing Second Quarter 2017 Corporate Update and Results
07 août 2017 08h00 HE
|
Editas Medicine
CAMBRIDGE, Mass., Aug. 07, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on...
Editas Medicine to Participate in Investor Conferences in June
13 juin 2017 08h00 HE
|
Editas Medicine
CAMBRIDGE, Mass., June 13, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that management will participate in two upcoming investor...